Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 3
2007 6
2008 8
2009 8
2010 8
2011 7
2012 5
2013 11
2014 11
2015 18
2016 16
2017 16
2018 9
2019 9
2020 5
2021 12
2022 10
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean wen jian zheng (16 results)?
Inflammasomes and Fibrosis.
Zhang WJ, Chen SJ, Zhou SC, Wu SZ, Wang H. Zhang WJ, et al. Front Immunol. 2021 Jun 11;12:643149. doi: 10.3389/fimmu.2021.643149. eCollection 2021. Front Immunol. 2021. PMID: 34177893 Free PMC article. Review.
The hepatocyte in the innate immunity.
Zhang WJ, Li KY, Huang BH, Wang H, Wan SG, Zhou SC. Zhang WJ, et al. Virology. 2022 Nov;576:111-116. doi: 10.1016/j.virol.2022.09.011. Epub 2022 Oct 6. Virology. 2022. PMID: 36209694 Free article. Review.
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, Chen Q, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Kaklamani V, Bertucci F, Verschraegen C, Daemen A, Shah NM, Wang T, Guo T, Shi L, Perou CM, Zheng Y, Huang W, Shao ZM. Jiang YZ, et al. Among authors: zhang wj. Nat Cancer. 2024 Feb 12. doi: 10.1038/s43018-024-00725-0. Online ahead of print. Nat Cancer. 2024. PMID: 38347143
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Fan L, et al. Among authors: zhang wj. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8. Lancet Oncol. 2024. PMID: 38211606 Clinical Trial.
162 results